Jeff Lagasse
The agency's goal is to ensure states and localities have the flexibility they need to ramp up diagnostic testing and access to medical care.
With a precipitous drop in volume, some organizations are going back to basics from a revenue cycle standpoint.
The process kills germs from N95 masks while ensuring that the only person who touches the mask is the original mask-wearer.
Even when asked to suspect themselves infected, 9% would still avoid treatment, suggesting gaps in coverage or poor finances.
Hospitals should be planning early for equipment, beds and people, and listening to epidemiologists about the kinds of numbers to expect.
Consumers may take a more active role in managing health and participating in a system that is essentially being remade.
By automating certain data-driven tasks, administrative waste can be dramatically reduced and RCM operations can move more efficiently.
Providers should seek ways to automate the process as much as possible to curtail the manual work involved.
Gene therapy delivered through the adeno-associated virus is likely the most attractive alternative treatment until a vaccine is produced.
If 20% of the US population were to become infected with COVID-19, it would result in an average of $163.4 billion in direct medical costs.